Related Experiment Video

Updated: Aug 8, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 19, 2013

Tyrosine kinase inhibitors

P Workman1, V G Brunton, D J Robins

  • 1CRC Department of Medical Oncology, University of Glasgow, Bearsden, UK.

Seminars in Cancer Biology
|December 1, 1992
PubMed

Insights

Tyrosine kinase inhibitors show promise as cancer drugs, with many identified inhibitors demonstrating cytostatic activity in lab models. These inhibitors are likely to enter clinical trials for cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Tyrosine kinases are crucial in cell signaling pathways, regulating growth factor receptors and oncoproteins.
  • Aberrant tyrosine kinase activity, due to mutation or overexpression, can drive cancer development.
  • Targeting tyrosine kinases offers a promising strategy for novel cancer therapeutics.

Purpose of the Study:

  • To review the progress in developing tyrosine kinase inhibitors for cancer treatment.
  • To assess the potential of various structural classes of tyrosine kinase inhibitors.
  • To discuss the future clinical applications of tyrosine kinase inhibitors in oncology.

Main Methods:

  • Literature review of identified tyrosine kinase inhibitors.
  • Analysis of in vitro and in vivo studies demonstrating cytostatic and anti-cancer activity.
  • Evaluation of different structural classes and their therapeutic potential.

Main Results:

  • Numerous tyrosine kinase inhibitors have been identified.
  • Many inhibitors exhibit significant cytostatic activity in preclinical (in vitro) models.
  • Some promising in vivo activity has been reported for select inhibitors.
  • Progress across various structural classes of inhibitors is detailed.

Conclusions:

  • Tyrosine kinases are validated targets for anticancer drug development.
  • Tyrosine kinase inhibitors have demonstrated significant preclinical efficacy.
  • Further research is needed to determine optimal inhibitor strategies (specific vs. broad spectrum).
  • Tyrosine kinase inhibitors are anticipated to enter clinical trials for cancer patients.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: